Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. 
Introduction
The elucidation of the pathophysiology of TTP and HUS, in the past 20 years, has transformed our understanding of the phenotypes, genotypes and therapies for these life-threatening conditions. Work on standardization has been addressed [1] , but this document aims to develop robust criteria for future clinical use, studies and trials.
Clinical and pathophysiologic features of TTP, atypical Hemolytic Uremic Syndrome (aHUS) and disorders with similar presentations, their investigation and subsequent management vary. This consensus document aims to rationalize and standardize definitions. Conditions often included in the initial differential diagnosis of TTP are discussed. Definitions for remission, refractory and relapsing disease are defined.
ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1
motif, member 13) assays are central to diagnosis and are discussed. We therefore also describe the minimum requirements for validation of current and future assays.
Methods:
The development of this document involved key international, primarily clinical, experts in TTP and related TMAs. 
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Hemostasis (ISTH) and American Society of Hematology (ASH) and all versions of
the document have been reviewed and edited by the authors. Articles were identified by a computer-assisted search of the literature published in English using the National Library of Medicine PubMed database. The authors also undertook a focused review of the available literature. Where there was a lack of robust evidence, the international working group concluded a consensus-based approach was preferable. The conclusions are relevant to both children and adults.
Thrombotic Microangiopathy
The term TMA is a pathological term used to describe occlusive microvascular or macrovascular disease, often with intraluminal thrombus formation, but is also defined clinically by microangiopathic hemolytic anemia and thrombocytopenia (MAHAT). This does not specifically define a condition; therefore further investigations are required to identify the underlying cause for the presentation of a TMA, including TTP (Figure 1 ). (iii) Thrombotic Microangiopathy; characterized by endothelial swelling or disruption associated with hyalinosis or fibrinoid necrosis, usually without an inflammatory cell infiltrate. Chronic TMA is associated with myointimal proliferation resulting in
Pathological Features of TMAs
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Clinical features of TMAs
Peripheral blood film features consistent with MAHA include fragmented red blood cells (schistocytes), polychromasia and anemia. Quantification of fragmentation/schistocytes is not reliably available and remains subjective.
Laboratory evidence of hemolysis includes elevated lactate dehydrogenase (LDH), reticulocytosis, low/absent haptoglobin, and a negative direct antiglobulin test.
Thrombocytopenia will be evident in the complete blood count (CBC) and on the blood film [10] . 
Thrombotic thrombocytopenic purpura (TTP)
Definition
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Presentation with renal failure requiring renal replacement is not a common feature of TTP. However, occasionally patients with multi organ failure may develop an acute kidney injury requiring renal support. Congenital TTP (cTTP) patients may present with acute renal failure [12] . cTTP cases may previously have been misclassified as HUS [13] Acute TTP presentations may include bleeding symptoms such as bruising, hematuria or thrombotic symptoms associated with neurological or cardiac involvement. In practice, TTP is suspected in:
• Isolated MAHAT
• New focal neurological symptoms, seizures or myocardial infarction (MI), with unexplained MAHAT
• Prior history of TTP
Confirming a diagnosis of TTP:
Current ADAMTS-13 activity assays provide levels of sensitivity <5% or 1%.
However, for the diagnosis of TTP, ADAMTS-13 activity levels < 10% are diagnostic. This is to include antibody mediated cases and cTTP, including late onset cTTP.
The diagnosis of TTP should be confirmed with ADAMTS-13 activity performed on a sample taken prior to initiation of therapy, specifically plasma-based. Samples taken immediately following plasma therapy may give a falsely raised ADAMTS-13 activity.
The presence of anti-ADAMTS-13 IgG antibodies may help confirm TTP in these situations. However, in autoimmune TTP, >75% of patients exhibit <10% ADAMTS-13 activity immediately before the next therapeutic plasma exchange session for several days after starting daily exchange therapy [14] .
Assays at diagnosis should include: ADAMTS-13 activity, functional inhibitor based on mixing studies, and/or an anti-ADAMTS-13 IgG. This panel should correctly identify TTP patients in the majority of cases.
Measurement of ADAMTS-13 at regular intervals during treatment and in remission (e.g. weekly during treatment, monthly, then 3 monthly during follow-up period, extending to 6-12 monthly) may provide data in regard to the risk of relapse and
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persistence of subclinical disease activity [15] . ADAMTS-13 activity <10% with or without a detectable inhibitor is associated with a significant risk of relapse and can guide elective, prophylactic therapy preventing further relapse [16] [17] [18] Persistent ADAMTS-13 activity <10% with no detectable anti-ADAMTS-13 IgG antibodies (confirmed in the acute phase and in remission after treatment) suggests a diagnosis of cTTP, especially in the following circumstances:
• Neonates presenting with thrombocytopenia, red cell fragmentation on blood film, often with hyperbilirubinemia.
• Children/ adults if there is a familial antecedent of TTP, especially in siblings from consanguineous parents.
• First TTP episode in adulthood, in particular, during pregnancy. The diagnosis is confirmed if pathogenic ADAMTS-13 mutations are identified.
However, many genetic variants are of unknown significance and require expression studies. Infusion of plasma resulting in recovery of ADAMTS-13 activity and the disappearance of ADAMTS-13 activity with a half life of 2-3 days, supports the diagnosis of cTTP [26] .
Immune mediated TTP (iTTP):
This defines acquired TTP and can be divided into those cases in which a precipitating cause can or cannot be confirmed. All cases require immediate therapy (TPE and steroids), but differentiating subgroups can help to tailor therapy. 
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There remain, however, a number of cases that meet the clinical criteria for TTP, but with ADAMTS-13 activity levels that are not severely deficient and in whom an alternative diagnosis cannot be determined. In these patients treatment with plasma exchange, needs to be individualized and continued only if a clear clinical benefit is obvious. Such cases should be discussed with expert centres in TTP/HUS.
Differential diagnosis of TMA
There are a number of conditions that have presenting features (both clinical and laboratory) similar to TTP. ADAMTS-13 assays are essential in their differentiation (Table 1) .
Hemolytic Uremic Syndrome (HUS): HUS is defined by MAHAT and renal
injury, which is the predominant feature. Thrombocytopenia may not be as severe as in TTP, and anemia at presentation can be variable (Figure 1 ).
Infection Associated HUS (IA-HUS), often referred to as STEC-HUS describes an
infectious etiology associated typically with E. coli 0157:H7, that express Shiga toxin.
The TMA presents 5-7 days after the infection with hemorrhagic colitis. E coli 0157:
H7 is not the only subtype associated with infection associated HUS. Indeed other subtypes of E coli [36] , Salmonella, Shigella, and Campylobacter associated HUS can present similarly.
Complement Mediated HUS (CM-HUS)
usually results from defective regulation of the alternative complement pathway [37] . CM-HUS can be triggered by infection (and diarrhea may be evident at presentation), vaccinations, or pregnancy.
Heterozygous mutations may be identified, affecting complement regulators including complement factors H (CFH) and I (CFI), complement factor H related protein (CFHR1, 3 and 5), CD46 (MCP), or gain of function mutations in C3 and complement factor B (CFB). CM-HUS associated with anti-complement factor H antibodies (associated with a polymorphic deletion of CFHR1) can also occur, particularly in children, and is responsive to immunosuppressive therapy [38] . CM-HUS is also described associated with defects in other genes, including THBD, which encodes thrombomodulin and with bi-allelic mutation of the DGKE gene that encodes diacycl glycerol kinase ε, which regulates diacyl glycerol activated Protein
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Kinase C signaling in endothelial cells. While the pathophysiology of DGKEassociated HUS is not completely understood it is not thought to directly involve disruption of complement alternative pathway regulation [39] .
Mutational analysis may take weeks to be completed and in 40-50% of cases no mutations are identified [40] . Therefore, treatment decisions must be made on the basis of the clinical presentation and absence of severe ADAMTS-13 deficiency.
CM-HUS may respond to plasma exchange but eculizumab, a humanized monoclonal antibody, which binds to and inhibit C5, is more efficacious, except in DGKE-associated disease [41] . In addition, new complement inhibitors are being developed. A C5 polymorphism, described in the Japanese population, is associated with a reduced response to eculizumab [42] .
The clinical presentation of CM-HUS can be variable and includes:
• renal failure, MAHAT;
• renal failure with MAHA but a normal platelet count;
• chronic or progressive renal failure, without a history of MAHA;
• severe hypertension, MAHA or thrombocytopenia, with or without renal impairment, often diagnosed by renal biopsy.
In addition to molecular testing, a response to anti-complement therapy may provide confirmation of the diagnosis.
Rare secondary causes have been identified causing HUS [43] (Table 1) . 
Definition of hematological response to treatment
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This article is protected by copyright. All rights reserved. The definition of refractory TTP can be challenging. Cases with an initial response, but then a reduced platelet count that is difficult to increase, may be considered refractory and this may occur after 5 plasma exchange procedures. However, the clinical condition is likely to be more stable at this point.
Intensive plasma exchange refers to increased volumes per plasma exchange eg a single volume to 1.5 plasma volume or increased frequency of plasma exchange eg twice daily. Protocols will be institution specific.
During an acute presentation, the definition of refractory disease may require an escalation in therapy. The median time to achieve a clinical response, with daily plasma exchange, is approximately 10-15 days [45] . Patients admitted to an ICU setting with neurological and /or cardiac features may require longer plasma exchange therapy [46] . Patients failing to achieve remission or whose platelet count and LDH initially improve but worsen despite on-going treatment would also be considered to have refractory disease.
Relapsing TTP:
There are a number of identified risk factors that may be associated with or precipitate a relapse of iTTP,
• ADAMTS-13 deficiency (particularly <10% activity)
• Persistent severe ADAMTS-13 deficiency in remission
• Persistent anti-ADAMTS-13 antibodies in remission or congenital disease
• Pregnancy
• Infection/live vaccinations
• Drugs including drugs of abuse eg. cocaine, alcohol
In iTTP, a severely reduced ADAMTS-13 activity persisting during remission is associated with relapse, particularly when associated with inhibitory autoantibodies [47] . Therapy should be considered to clear antibodies and normalize ADAMTS-13 activity, in patients felt to be at high risk for relapse [16, 18] . Pregnancy [48] , infections and live vaccinations in particular may precipitate an acute episode of cTTP. Often, an initial acute TTP episode, even though occurring only in adulthood, is followed by recurrent episodes [49] .
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This article is protected by copyright. All rights reserved. Low ADAMTS-13 antigen level at presentation may be associated with worse clinical outcome in iTTP [53] . Routine laboratory parameters such as platelet count, LDH, and hemoglobin are not predictive of severity, although failure to improve with therapy and hence refractory disease is associated with a worse outcome.
ADAMTS-13 assays:
ADAMTS-13 activity: determines the amount of functional ADAMTS-13 via direct or indirect measurement of VWF cleavage. Current methods include FRETS-VWF73, chromogenic VWF-73 [54] , chromogenic VWF-73 [55] , FRETS-rVWF71 [56] FRET-VWF86 and SELDI-TOF mass spectrometry [57] . A standard curve using pooled normal plasma (PNP) for each assay plus control samples (e.g. plasma of a cTTP patient for an low range sample; the WHO 1st International Standard ADAMTS-13 [58] ), which have undergone in-house calibration.
ADAMTS-13 antigen: determines the amount of ADAMTS-13 protein in plasma. Low levels appear to be associated with poor prognosis [53] .
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Anti-ADAMTS-13 antibodies: usually IgG but IgM and IgA may be also relevant. Anti-ADAMTS-13 antibodies are measured by ELISA, Western blot or immunoprecipitation. ADAMTS-13 antibodies by ELISA may be seen in 5%-10% of healthy individuals however, this may be manufacturer/assay dependent [59] . ELISA or Western blotting using recombinant ADAMTS-13 to detect anti-ADAMTS-13 in patient's plasma can assess the presence of anti-ADAMTS-13 antibodies. In-house or commercially available assays should have appropriate validation and controls to include low, medium and high antibody titres.
ADAMTS-13 inhibitor assays: identifies and quantitates anti-ADAMTS-13 antibodies
that functionally inhibit ADAMTS-13 in vitro. Functional ADAMTS-13 inhibitors are assessed in classical Bethesda-like mixing studies. Samples are heat-inactivated for 30 minutes at 56°C to abolish endogenous ADAMTS-13, before mixing, at various dilutions, with PNP. After incubation at 37°C for 2 hours, residual ADAMTS-13 activity is measured and the residual activity transformed in Bethesda units,(1BU/ml of inhibitor inhibits 50% of normal plasma ADAMTS-13). For routine purposes it is usually sufficient to titrate up to 2 Bethesda units/ml.
Factors affecting ADAMTS-13 levels
Severe hemolysis with marked hyperbilirubinemia [60] or severe lipemia may give falsely low ADAMTS-13 activity results, particularly when using fluorogenic detection e.g. FRETS [54] ; Free hemoglobin in plasma from intravascular hemolysis can also inhibit ADAMTS-13 activity [61] .
There is good concordance between assays in the range of severe deficiency of ADAMTS-13 (defined as either <5% or <10%). However assay conditions can affect results. There are numerous variables in quantification of ADAMTS-13 activity levels among different platforms or when performed in different laboratories. Further studies involving large series of plasma samples are needed to evaluate the newly developed commercial kits.
Pre-analytic aspects: specimen type and acceptability criteria
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ADAMTS-13 activity can be assessed in citrated plasma, serum or lithium-heparin plasma. While extensive comparisons between these are missing, small series demonstrate equality [62] . EDTA plasma is not suitable for ADAMTS-13 activity testing, as it is an irreversible inhibitor of ADAMTS-13 activity.
Evaluation of assays -Detection (sensitivity) limit of the method:
. For ADAMTS-13 activity measurement (defined as the lowest activity that is distinguishable from buffer or heat inactivated plasma respectively): this should be < 5%, but preferably < 1%.
. For the detection of inhibitors: difficult to standardize, but a negative control and at least 2 positive antibody controls, which have demonstrated reproducibility with the technique, should be considered. The detection limit is approximately 0.4-0.6 BU/ml.
-Precision of the method: intra-assay reproducibility (within series), inter-assay reproducibility (between run in one given laboratory and also inter-laboratory precision): should have CVs of <10%.
In conclusion, we have developed definitions for TTP and associated TMAs that we hope will promote uniformity in publications, associated studies and clinical trials.
The field is ever expanding and the group will be required to undertake a review again in future years. 
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B. Pre-eclampsia
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